These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3472424)

  • 21. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.
    Kalkman JS; Schillings ML; van der Werf SP; Padberg GW; Zwarts MJ; van Engelen BG; Bleijenberg G
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1406-9. PubMed ID: 16170086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rehabilitation interventions for foot drop in neuromuscular disease.
    Sackley C; Disler PB; Turner-Stokes L; Wade DT; Brittle N; Hoppitt T
    Cochrane Database Syst Rev; 2009 Jul; (3):CD003908. PubMed ID: 19588347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population study of adult onset limb-girdle muscular dystrophy.
    Yates JR; Emery AE
    J Med Genet; 1985 Aug; 22(4):250-7. PubMed ID: 4045950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Child neuromuscular disease in southern Norway. Prevalence, age and distribution of diagnosis with special reference to "non-Duchenne muscular dystrophy".
    Tangsrud SE; Halvorsen S
    Clin Genet; 1988 Sep; 34(3):145-52. PubMed ID: 3263224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy.
    Merlini L; Stagni SB; Marri E; Granata C
    Neuromuscul Disord; 1992; 2(3):197-200. PubMed ID: 1483045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of relatives on fatigue experienced by patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I.
    Kalkman JS; Schillings ML; Zwarts MJ; van Engelen BG; Bleijenberg G
    Eur Neurol; 2006; 56(1):24-30. PubMed ID: 16914927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Incidence of spinal muscular atrophy and Duchenne's muscular dystrophy in the juvenile population of central Slovakia].
    Kvasnicová M; Styková J; Hudec P
    Bratisl Lek Listy; 1994 Feb; 95(2):78-82. PubMed ID: 7922631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I.
    Kalkman JS; Schillings ML; Zwarts MJ; van Engelen BG; Bleijenberg G
    Acta Neurol Scand; 2007 Apr; 115(4):265-70. PubMed ID: 17376125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden.
    Darin N; Tulinius M
    Neuromuscul Disord; 2000 Jan; 10(1):1-9. PubMed ID: 10677857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible neurogenic factor in muscular dystrophy: its similarity to denervation atrophy.
    Dastur DK; Razzak ZA
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):399-410. PubMed ID: 4714102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to immunosuppressive therapy in patients with hereditary motor and sensory neuropathy and associated dysimmune neuromuscular disorders.
    Mitchell GW; Bosch EP; Hart MN
    Eur Neurol; 1987; 27(3):188-96. PubMed ID: 3476306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature.
    Deenen JC; Horlings CG; Verschuuren JJ; Verbeek AL; van Engelen BG
    J Neuromuscul Dis; 2015; 2(1):73-85. PubMed ID: 28198707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of neuromuscular diseases on the development of dental and occlusal characteristics.
    Ertürk N; Doğan S
    Quintessence Int; 1991 Apr; 22(4):317-21. PubMed ID: 1891607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunochemical study of connectin (titin) in neuromuscular diseases using a monoclonal antibody: connectin is degraded extensively in Duchenne muscular dystrophy.
    Matsumura K; Shimizu T; Nonaka I; Mannen T
    J Neurol Sci; 1989 Nov; 93(2-3):147-56. PubMed ID: 2592979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Charcot-Marie-Tooth disease in northern Sweden: an epidemiological and clinical study.
    Holmberg BH
    Acta Neurol Scand; 1993 May; 87(5):416-22. PubMed ID: 8333247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromuscular diseases associated with benign monoclonal gammopathy. Study of CSF and serum proteins by isoelectric focusing.
    Poloni M; Rocchelli B; Pinelli P; Scelsi R
    Acta Neurol Scand; 1982 Feb; 65(2):154-9. PubMed ID: 6951387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire.
    Vandervelde L; Van den Bergh PY; Goemans N; Thonnard JL
    Neuromuscul Disord; 2009 Feb; 19(2):99-103. PubMed ID: 19167889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orthopedic management of neuromuscular disorders in children.
    Birch JG
    Semin Pediatr Neurol; 1998 Jun; 5(2):78-91. PubMed ID: 9661242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature.
    Reimers CD; Schlotter B; Eicke BM; Witt TN
    J Neurol Sci; 1996 Nov; 143(1-2):46-56. PubMed ID: 8981297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of progressive muscular dystrophy in Okinawa, Japan. Classification with molecular biological techniques.
    Nakagawa M; Nakahara K; Yoshidome H; Suehara M; Higuchi I; Fujiyama J; Nakamura A; Kubota R; Takenaga S; Arahata K
    Neuroepidemiology; 1991; 10(4):185-91. PubMed ID: 1745328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.